Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · IEX Real-Time Price · USD
4.190
+0.080 (1.95%)
At close: May 3, 2024, 4:00 PM
4.220
+0.030 (0.72%)
After-hours: May 3, 2024, 4:53 PM EDT
Autolus Therapeutics Revenue
In the year 2023, Autolus Therapeutics had annual revenue of $1.70M, a decrease of -73.30%.
Revenue (ttm)
$1.70M
Revenue Growth
-73.30%
P/S Ratio
429.61
Revenue / Employee
$3,667
Employees
463
Market Cap
729.48M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
Dec 31, 2019 | 2.91M | 1.50M | 106.68% |
Sep 30, 2018 | 1.41M | -286.00K | -16.89% |
Sep 30, 2017 | 1.69M | 481.00K | 39.69% |
Sep 30, 2016 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Atrion | 169.33M |
Arcturus Therapeutics Holdings | 166.80M |
Wave Life Sciences | 113.31M |
AnaptysBio | 17.16M |
Mobile-health Network Solutions | 7.87M |
AUTL News
- 10 days ago - Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO - GlobeNewsWire
- 11 days ago - Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics Announces Changes to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site - GlobeNewsWire
- 2 months ago - Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 - GlobeNewsWire
- 3 months ago - Autolus Announces Pricing of Underwritten Offering - GlobeNewsWire
- 3 months ago - BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs - GlobeNewsWire